Please use this identifier to cite or link to this item: https://islhd.intersearch.com.au/islhdjspui/handle/1/5534
Title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre
open-label
global
phase 3
randomised
controlled trial
ISLHD Author: Clingan, Philip
Authors: Sezer A;Kilickap S;Gümüş M;Bondarenko I;Özgüroğlu M;Gogishvili M;Turk HM;Cicin I;Bentsion D;Gladkov O;Clingan P;Sriuranpong V;Rizvi N;Gao B;Li S;Lee S;McGuire K;Chen CI;Makharadze T;Paydas S;Nechaeva M;Seebach F;Weinreich DM;Yancopoulos GD;Gullo G;Lowy I;Rietschel P.
Keywords: Pharmacology;Oncology
Date Published: 14-Feb-2021
Citation: Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2.
URI: https://islhd.intersearch.com.au/islhdjspui/handle/1/5534
Appears in Collections:Research publications from current and former ISLHD staff.

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.